CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Bicycle Therapeutics PLC (ADR) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Bicycle Therapeutics PLC (ADR)
Blocks A & B, Portway Building, Granta P
Phone: +44 1223261503p:+44 1223261503 CAMBRIDGE, CB21 6GS  United Kingdom Ticker: BCYCBCYC
Business Summary
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist (TICA). The Company is also focused on additional therapeutic areas other than its wholly owned oncology portfolio.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board PierreLegault 62 3/1/2019 3/1/2019
Chief Executive Officer, Executive Director KevinLee 55 9/1/2015 9/1/2015
Chief Financial Officer, Principal Financial Officer Alethia R.Young 45 7/17/2023 7/17/2023
10 additional Officers and Directors records available in full report.

Business Names
Business Name
BCYC
Bicycle
Bicycle Therapeutics Inc.
Bicycle Therapeutics Limited
BicycleRD Limited
BicycleTx Limited

General Information
Number of Employees: 284 (As of 12/31/2023)
Outstanding Shares: 42,586,185 (As of 2/15/2024)
Shareholders: 45
Stock Exchange: NASD


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024